In continuation of their joint company announcement of July 23, 2014, BioAlliance Pharma SA (Euronext Paris – BIO), an innovative company specialized in the development of drugs in orphan oncology diseases newly renamed Onxeo, and Topotarget A/S (NASDAQ OMX Copenhagen – TOPO), today announce that NASDAQ OMX Copenhagen has approved Onxeo’s admission to secondary trading and official listing on NASDAQ OMX Copenhagen to be effective as of August 1, 2014. From this date, BioAlliance Pharma as the continuing entity after the merger will also officially operate under the name Onxeo.
“We are very happy and proud of this final step marking the starting point for our new identity. Onxeo’s teams are ready and determined to unleash their synergistic potential to shape a dynamic player in the orphan oncology market”, declares Judith Greciet, Chief Executive Officer of Onxeo.
“With the combination of team’s expertise and a robust and innovative pipeline, Onxeo has solid basis to successfully conduct its mission to develop innovative drugs and provide patients with hope and significantly improve their lives”, declares Anders Vadsholt, Chief Executive Officer of Topotarget.
For more information on Onxeo reference is made to the admission prospectus of May 26, 2014 prepared by Onxeo and the company announcements issued by Onxeo, which are available on Onxeo’s website (www.onxeo.com). There has been no adverse material change in Onxeo compared with the information provided in the admission prospectus dated May 26, 2014.
BioAlliance Pharma’s shares (including the newly issued shares) will remain admitted to trading on Euronext Paris under the name Onxeo (ticker: ONXEO).
The exchange of the Topotarget A/S shares against Onxeo’s new ordinary shares in accordance with the merger plan is expected to occur on August 5, 2014.
Issuance of legality certificate by French authority: July 22, 2014
Registration by the Danish Business Authority of completion of the merger and deregistration of Topotarget A/S: July 28, 2014
Last day of trading of Topotarget A/S on NASDAQ OMX Copenhagen: July 31, 2014
Admission to trading of Onxeo’s new ordinary shares on Euronext Paris: August 1, 2014
Name change to Onxeo effective on Euronext Paris: August 1, 2014
First day of trading of Onxeo SA on NASDAQ OMX Copenhagen in ISIN FR0010095596 (ticker: ONXEO): August 1, 2014
Exchange of Topotarget shares with new ordinary shares in Onxeo SA through VP Securities (end of day) in accordance with the exchange ratio defined in the merger plan (2 Onxeo shares for each set of 27 Topotarget shares): August 5, 2014
Settlement of payment for fractional entitlements: August 6, 2014